Skip to main navigation
logo
logo

Investor Relations

  • Overview
  • Financials
    • SEC Filings
  • Governance
    • Governance Highlights
    • Management Team
    • Board of Directors
    • Committee Composition
    • Board Diversity Matrix
  • News & Events
    • Press Releases
    • Investor Calendar
    • Presentations
  • Stock
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

Investor Relations

IsoPlexis is dedicated to accelerating the fight against cancer and a range of our toughest diseases by producing the world’s most precise, award-winning detection systems. By revealing unique immune biomarkers in small subsets of cells, we are advancing immunotherapies and targeted therapies to a more highly precise & personalized stage.

Change
Minimum 15 minutes delayed. Mar 25, 2023 12:04 AM EDT
Data Provided by Refinitiv.

Presentations

Investor Presentation

Press Releases

Jan 12, 2023
IsoPlexis Reports Preliminary Full Year 2022 Revenue
Dec 21, 2022
Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company
Nov 10, 2022
IsoPlexis Reports Third Quarter 2022 Financial Results

Site - View All - News

  • View All

Recent Events

Dec 21, 2022 at 5:00 PM EST
Berkeley Lights to Acquire Isoplexis Investor Conference Call & Presentation
Click Here for Webcast
Dec 01, 2022 at 12:10 PM EST
Evercore ISI 5th Annual HealthCONx Conference
Click Here for Webcast
Nov 10, 2022 at 8:30 AM EST
IsoPlexis Third Quarter 2022 Earnings Conference Call
Click Here for Webcast

Site - View All - Events

  • View All

Corporate Governance

Sean Mackay

CEO & CO-FOUNDER

Sean Mackay

CEO & CO-FOUNDER

Sean Mackay co-founded and leads IsoPlexis as CEO. IsoPlexis’ mission is to provide widely accessible cellular proteomics to speed personalized, curative medicines. The company focuses on shifting paradigms in cell and gene therapy, cancer immunology, and infectious disease towards more patient specific, long lasting treatments. IsoPlexis’ easy to use instrumentation and software have won numerous awards and are used globally to advance precision medicine.

Previously, Sean helped incubate Kleiner Perkins-backed Lifesquare, which connected patients, payers, and providers through sharing essential healthcare information.  Additionally, through work at Lazard and with several early-stage ventures, he developed a passion for helping life sciences and medical device companies manage in times of strategic change, to deliver their highly needed products to the clinical ecosystem. Sean has co-authored a number of publications centered around immune medicines and holds patents for a number of single-cell products worldwide.

John G. Conley

CHAIRMAN OF BOARD

John G. Conley

CHAIRMAN OF BOARD

John co-founded Gilliam Capital LLC, a life science investment firm, and is a member of Launchpad Venture Group in Boston. He is a board member for three healthcare startups and works with a variety of social enterprises. He is currently the Chief Operating Officer of Entrepreneurship for All, a nonprofit that is accelerating economic and social impact through fostering entrepreneurship in mid-sized cities. He was a co-founder of the RNA interference therapeutics company Alnylam Pharmaceuticals where he held the position of Vice President, Strategy and Finance and CFO through to its successful 2004 IPO. He was Vice President of Business Development at Transkaryotic Therapies through to its acquisition by Shire Pharmaceuticals. Over ten years at Biogen he served in several marketing, business development, sales and finance positions, including Country Manager – United Kingdom and Ireland, and Treasurer. He was a Manager at the strategy-consulting firm of Bain & Company. John graduated with a BS in Economics from the University of Pennsylvania’s Wharton School and an MBA from the Yale School of Management. He was a 2014 Fellow in the Advanced Leadership Initiative at Harvard University.

Gregory P. Ho

BOARD DIRECTOR

Gregory P. Ho

BOARD DIRECTOR

Greg has served as the President of Spring Mountain Capital since its founding in June 2001. Previously, he was a Principal and Chief Financial Officer of McKinsey & Company, Inc. During his 16 years with McKinsey, he led the financial and tax planning for the firm and its worldwide partner group, as well as the identification, evaluation, and selection of traditional and alternative asset managers for over $1 billion of assets in its qualified employee plans and in-house investment office. Greg was also a Trustee of McKinsey’s Profit-Sharing Retirement Plan and a member of the firm’s Investment Committee. After leaving McKinsey in 1998 and prior to joining SMC, Greg was a private investor and consultant. Prior to joining McKinsey, he was associated with the law firm of Donovan Leisure Newton & Irvine. Greg is currently a member of the Advisory Council of the Yale Entrepreneurship Institute and a member of the Investor Board of Venture for America. He received a J.D. from Columbia Law School and a B.S., with honors, in Administrative Science from Yale College. He is a member of the New York Bar and the California Bar.

Daniel Wagner

BOARD DIRECTOR

Daniel Wagner

BOARD DIRECTOR

Dan serves as a Managing Director of Investments at Connecticut Innovations and is an active board member of multiple life sciences companies. Dan contributes to CI’s expertise in biotech with more than 10 years in the industry. He was previously employed by CuraGen Corporation, where he held a variety of scientific and operational management positions. He holds an M.B.A. and M.H.S. degree in Biomedical Sciences from Quinnipiac University, and a B.S. degree in Biology from the University of Dayton.

James R. Heath, Ph.D.

BOARD DIRECTOR AND SCIENTIFIC ADVISORY BOARD MEMBER

James R. Heath, Ph.D.

BOARD DIRECTOR AND SCIENTIFIC ADVISORY BOARD MEMBER

Jim is the Elizabeth W. Gilloon Professor and Professor of Chemistry at Caltech, and Professor of Molecular & Medical Pharmacology at the University of California, Los Angeles (UCLA), and Director of the National Cancer Institute’s NSB Cancer Center. He has founded or co-founded several companies, including NanoSys, MTI, Sofie Biosciences, and Indi Dx, and has served on the board of a number of organizations including the Board of Scientific Advisors of the National Cancer Institute. Jim graduated with a degree in Chemistry from Baylor University in Texas. He completed his Ph.D. in Physics and Chemistry from Rice University. He was awarded the 2000 Feynman Prize in Nanotechnology. He became a fellow of American Physical Society in 1999 and in 2009 he was named one of the seven most powerful innovators of the world by Forbes magazine.

Jason Myers, Ph.D.

BOARD MEMBER

Jason Myers, Ph.D.

BOARD MEMBER

Adam Wieschhaus, Ph.D., CFA

BOARD MEMBER

Adam Wieschhaus, Ph.D., CFA

BOARD MEMBER

Nachum Shamir

BOARD DIRECTOR

Nachum Shamir

BOARD DIRECTOR

Site - Investor Tools

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Contact IR
  • Search

© 2023 IsoPlexis      All rights reserved.

Site - Footer - Bottom Nav

  • Privacy Policy
  • Terms and Conditions
  • Facebook
  • Twitter
  • LinkedIn
  • Google+